Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Leadartis S L is currently navigating the patent prosecution process within the Biotechnology & Pharmaceuticals technology area. The company's portfolio presently includes 1 pending office action. This action is being reviewed by 1 distinct examiner, which results in a prosecution effort concentrated under this individual.
The prosecution is further situated within 1 distinct art unit. JUEDES, AMY E is the busiest examiner for this portfolio, currently overseeing 1 pending office action. For the applicant, the immediate success of the intellectual property strategy depends on the review of this examiner. This structure, where 1 distinct examiner and 1 distinct art unit handle the workload, simplifies the management of the portfolio. There is no need to reconcile feedback from multiple sources within the patent office. The current data shows the company is pursuing patent rights in the Biotechnology & Pharmaceuticals sector through this point of contact. Practitioners can expect a consistent evaluation of technical claims under this arrangement.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| JUEDES, AMY E | 1 | 44.8% | +41.7% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18548442 | TRIMERIC POLYPEPTIDES AND USES THEREOF IN THE TREATMENT OF CANCER | JUEDES, AMY E | 10d overdue |
| Art Unit | Apps |
|---|---|
| 1644 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18548442 | TRIMERIC POLYPEPTIDES AND USES THEREOF IN THE TREATMENT OF CANCER | JUEDES, AMY E | 1644 | §103§112DP | Final Rejection | 10d overdue | Pending | Aug 30, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial